

Daniele Altomare

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8093708/publications.pdf>

Version: 2024-02-01

41
papers

1,906
citations

361296

20
h-index

302012

39
g-index

43
all docs

43
docs citations

43
times ranked

2563
citing authors

#	ARTICLE	IF	CITATIONS
1	Brain atrophy in Alzheimer's Disease and aging. Ageing Research Reviews, 2016, 30, 25-48.	5.0	507
2	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	4.9	203
3	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain ¹⁸ F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology, 2018, 25, 1201-1217.	1.7	153
4	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	3.3	86
5	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. JAMA Neurology, 2016, 73, 1417.	4.5	84
6	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1509-1525.	3.3	81
7	Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	3.3	61
8	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.5	55
9	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.5	51
10	Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation. Journal of Alzheimer's Disease, 2018, 65, 221-230.	1.2	44
11	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. Alzheimer's and Dementia, 2020, 16, 1457-1468.	0.4	43
12	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.4	37
13	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services" part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171.	3.0	37
14	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1557-1566.	3.3	35
15	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1487-1496.	3.3	35
16	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	3.0	35
17	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.4	29
18	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1526-1533.	3.3	28

#	ARTICLE	IF	CITATIONS
19	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Servicesâ€™ part 1 of 6. Alzheimer's Research and Therapy, 2021, 13, 168.	3.0	26
20	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1546-1556.	3.3	24
21	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.0	24
22	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.4	24
23	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	3.3	23
24	Dementia risk communication. A user manual for Brain Health Servicesâ€™ part 3 of 6. Alzheimer's Research and Therapy, 2021, 13, 170.	3.0	21
25	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486.	3.3	19
26	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2200-2211.	3.3	19
27	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	3.3	18
28	Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloidâ€PET. Alzheimer's and Dementia, 2018, 14, 1088-1098.	0.4	15
29	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. Alzheimer's Research and Therapy, 2021, 13, 105.	3.0	15
30	Protocols for cognitive enhancement. A user manual for Brain Health Servicesâ€™ part 5 of 6. Alzheimer's Research and Therapy, 2021, 13, 172.	3.0	15
31	Societal and equity challenges for Brain Health Services. A user manual for Brain Health Servicesâ€™ part 6 of 6. Alzheimer's Research and Therapy, 2021, 13, 173.	3.0	14
32	Medial temporal lobe atrophy and posterior atrophy scales normative values. NeuroImage: Clinical, 2019, 24, 101936.	1.4	12
33	Prognostic value of Alzheimerâ€™s biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	1.8	11
34	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?. Neurodegenerative Diseases, 2016, 16, 111-117.	0.8	6
35	Description of a European memory clinic cohort undergoing amyloidâ€PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.4	6
36	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 414-421.	0.4	5

#	ARTICLE	IF	CITATIONS
37	IS A LARGE-SCALE SCREENING FOR ALZHEIMER'S DISEASE POSSIBLE? YES, IN A FEW YEARS. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-2.	1.5	3
38	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. Alzheimer's and Dementia, 2020, 16, e042628.	0.4	1
39	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): Retrospective analyses on the Geneva Memory Clinic cohort. Alzheimer's and Dementia, 2020, 16, e045436.	0.4	1
40	Impact of the disclosure of amyloid PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS). Alzheimer's and Dementia, 2020, 16, e040952.	0.4	0
41	Towards fingerprinting and identifiability within the Alzheimer's continuum using resting-state functional connectivity. Alzheimer's and Dementia, 2021, 17, .	0.4	0